126 related articles for article (PubMed ID: 8089365)
1. Effect of peplomycin or camptothecin-11 on X-ray skin injuries of ICR hairless mice.
Kawahara K; Kano E; Ueda K
J Dermatol; 1994 Jul; 21(7):465-73. PubMed ID: 8089365
[TBL] [Abstract][Full Text] [Related]
2. Radiation enhancement by the combined use of topoisomerase I inhibitors, RFS-2000 or CPT-11, and topoisomerase II inhibitor etoposide in human lung cancer cells.
Kim JS; Amorino GP; Pyo H; Cao Q; Choy H
Radiother Oncol; 2002 Jan; 62(1):61-7. PubMed ID: 11830313
[TBL] [Abstract][Full Text] [Related]
3. Potentiation of murine MCa-4 carcinoma radioresponse by 9-amino-20(S)-camptothecin.
Kirichenko AV; Rich TA; Newman RA; Travis EL
Cancer Res; 1997 May; 57(10):1929-33. PubMed ID: 9157987
[TBL] [Abstract][Full Text] [Related]
4. Radiation lethality enhancement with 9-aminocamptothecin: comparison to other topoisomerase I inhibitors.
Lamond JP; Wang M; Kinsella TJ; Boothman DA
Int J Radiat Oncol Biol Phys; 1996 Sep; 36(2):369-76. PubMed ID: 8892462
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of radiation-induced DNA damage and inhibition of its repair by a novel camptothecin analog.
Huang G; Wang H; Yang LX
Anticancer Res; 2010 Mar; 30(3):937-44. PubMed ID: 20393017
[TBL] [Abstract][Full Text] [Related]
6. Effects of CPT-11 (a unique DNA topoisomerase I inhibitor) on a highly malignant xeno-transplanted neuroblastoma.
Komuro H; Li P; Tsuchida Y; Yokomori K; Nakajima K; Aoyama T; Kaneko M; Kaneda N
Med Pediatr Oncol; 1994; 23(6):487-92. PubMed ID: 7935175
[TBL] [Abstract][Full Text] [Related]
7. Mammalian DNA topoisomerase I mediates the enhancement of radiation cytotoxicity by camptothecin derivatives.
Chen AY; Okunieff P; Pommier Y; Mitchell JB
Cancer Res; 1997 Apr; 57(8):1529-36. PubMed ID: 9108456
[TBL] [Abstract][Full Text] [Related]
8. Effects of topoisomerase I-targeted drugs on radiation response of L5178Y sublines differentially radiation and drug sensitive.
Szumiel I; Buraczewska I; Gradzka I; Gasinska A
Int J Radiat Biol; 1995 Apr; 67(4):441-8. PubMed ID: 7738407
[TBL] [Abstract][Full Text] [Related]
9. Radiation enhancement by 9-aminocamptothecin: the effect of fractionation and timing of administration.
Kirichenko AV; Rich TA
Int J Radiat Oncol Biol Phys; 1999 Jun; 44(3):659-64. PubMed ID: 10348297
[TBL] [Abstract][Full Text] [Related]
10. Potentiation of radiation response in human carcinoma cells in vitro and murine fibrosarcoma in vivo by topotecan, an inhibitor of DNA topoisomerase I.
Kim JH; Kim SH; Kolozsvary A; Khil MS
Int J Radiat Oncol Biol Phys; 1992; 22(3):515-8. PubMed ID: 1310495
[TBL] [Abstract][Full Text] [Related]
11. Interaction of ionizing radiation with the topoisomerase I poison camptothecin in growing V-79 and HeLa cells.
Hennequin C; Giocanti N; Balosso J; Favaudon V
Cancer Res; 1994 Apr; 54(7):1720-8. PubMed ID: 8137287
[TBL] [Abstract][Full Text] [Related]
12. DNA damaging and cell cycle effects of the topoisomerase I poison camptothecin in irradiated human cells.
Falk SJ; Smith PJ
Int J Radiat Biol; 1992 Jun; 61(6):749-57. PubMed ID: 1351523
[TBL] [Abstract][Full Text] [Related]
13. Homocamptothecin, an E-ring-modified camptothecin analogue, generates new topoisomerase I-mediated DNA breaks.
Bailly C; Lansiaux A; Dassonneville L; Demarquay D; Coulomb H; Huchet M; Lavergne O; Bigg DC
Biochemistry; 1999 Nov; 38(47):15556-63. PubMed ID: 10569939
[TBL] [Abstract][Full Text] [Related]
14. Elevated topoisomerase I activity in cervical cancer as a target for chemoradiation therapy.
Chen BM; Chen JY; Kao M; Lin JB; Yu MH; Roffler SR
Gynecol Oncol; 2000 Nov; 79(2):272-80. PubMed ID: 11063656
[TBL] [Abstract][Full Text] [Related]
15. A novel molecular mechanism for anticancer drug-induced ovarian failure: Irinotecan HCl, an anticancer topoisomerase I inhibitor, induces specific FasL expression in granulosa cells of large ovarian follicles to enhance follicular apoptosis.
Utsunomiya T; Tanaka T; Utsunomiya H; Umesaki N
Int J Oncol; 2008 May; 32(5):991-1000. PubMed ID: 18425325
[TBL] [Abstract][Full Text] [Related]
16. Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ("Iressa") and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells.
Koizumi F; Kanzawa F; Ueda Y; Koh Y; Tsukiyama S; Taguchi F; Tamura T; Saijo N; Nishio K
Int J Cancer; 2004 Jan; 108(3):464-72. PubMed ID: 14648715
[TBL] [Abstract][Full Text] [Related]
17. Irinotecan (CPT-11) and characteristic mucosal changes in the mouse ileum and cecum.
Ikuno N; Soda H; Watanabe M; Oka M
J Natl Cancer Inst; 1995 Dec; 87(24):1876-83. PubMed ID: 7494232
[TBL] [Abstract][Full Text] [Related]
18. Delta-24 increases the expression and activity of topoisomerase I and enhances the antiglioma effect of irinotecan.
Gomez-Manzano C; Alonso MM; Yung WK; McCormick F; Curiel DT; Lang FF; Jiang H; Bekele BN; Zhou X; Alemany R; Fueyo J
Clin Cancer Res; 2006 Jan; 12(2):556-62. PubMed ID: 16428500
[TBL] [Abstract][Full Text] [Related]
19. Potent therapeutic activity of irinotecan (CPT-11) and its schedule dependency in medulloblastoma xenografts in nude mice.
Vassal G; Boland I; Santos A; Bissery MC; Terrier-Lacombe MJ; Morizet J; Sainte-Rose C; Lellouch-Tubiana A; Kalifa C; Gouyette A
Int J Cancer; 1997 Sep; 73(1):156-63. PubMed ID: 9334824
[TBL] [Abstract][Full Text] [Related]
20. Posttreatment exposure to camptothecin enhances the lethal effects of x-rays on radioresistant human malignant melanoma cells.
Boothman DA; Wang M; Schea RA; Burrows HL; Strickfaden S; Owens JK
Int J Radiat Oncol Biol Phys; 1992; 24(5):939-48. PubMed ID: 1332930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
